human cd36 Search Results


94
Miltenyi Biotec anti cd36 antibody
Anti Cd36 Antibody, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+cd36/CD36+Antibody%2C+anti-human/pm36522122-44-38-56
Average 94 stars, based on 1 article reviews
anti cd36 antibody - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

93
MedChemExpress compounds recombinant cd36 protein
Compounds Recombinant Cd36 Protein, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+cd36/CD36%2C+Human/pm40770043-59-6-13
Average 93 stars, based on 1 article reviews
compounds recombinant cd36 protein - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

94
Miltenyi Biotec cd36 pevio770
Flow cytometry antibodies used.
Cd36 Pevio770, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+cd36/CD36+Antibody%2C+anti-human%2C+REAfinity/pmc08070390-28-0-2
Average 94 stars, based on 1 article reviews
cd36 pevio770 - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

90
R&D Systems anti human cd36
Fig. 6 | <t>CD36</t> deficiency or CD36 blockade in vivo attenuates E protein- enhanced thrombosis. a Levels of CD36 in wild-type (WT) and CD36−/−mouse platelets. Results were confirmed in three independent experiments using platelets from different mice. b and c WT and CD36−/−mice were intravenously injected with the E protein (4 μg per mouse) or PBS 4 h before the pulmonary embolism (PE) model. b Quantification of the numbers of lung embolisms per visual field on lung sections. Data are mean ± SD of 25 counts from 5 mice in each group. c Representative field on lung sections by hematoxylin-eosin (HE) staining from WT and CD36−/−mice injected with the E protein or PBS. Scale bar = 100 μm. d and e Inferior vena cava (IVC) stenosis model was performed in WT and CD36−/−mice. WT and CD36−/−mice were pretreated with the E protein (4 μg per mouse) or PBS. d Representative image of the IVC thrombi. e The quantification analysis of the thrombi weight (n = 5). f and g WT mice were intraperitoneally injected with 10 mg/ kg SB203580 or DMSO. After 2 h, mice were intravenously infused with the E
Anti Human Cd36, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+cd36/Human+CD36%2FSR-B3+Antibody/pm37604832-271-59-64
Average 90 stars, based on 1 article reviews
anti human cd36 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

92
OriGene control shrna constructs
Fig. 6 | <t>CD36</t> deficiency or CD36 blockade in vivo attenuates E protein- enhanced thrombosis. a Levels of CD36 in wild-type (WT) and CD36−/−mouse platelets. Results were confirmed in three independent experiments using platelets from different mice. b and c WT and CD36−/−mice were intravenously injected with the E protein (4 μg per mouse) or PBS 4 h before the pulmonary embolism (PE) model. b Quantification of the numbers of lung embolisms per visual field on lung sections. Data are mean ± SD of 25 counts from 5 mice in each group. c Representative field on lung sections by hematoxylin-eosin (HE) staining from WT and CD36−/−mice injected with the E protein or PBS. Scale bar = 100 μm. d and e Inferior vena cava (IVC) stenosis model was performed in WT and CD36−/−mice. WT and CD36−/−mice were pretreated with the E protein (4 μg per mouse) or PBS. d Representative image of the IVC thrombi. e The quantification analysis of the thrombi weight (n = 5). f and g WT mice were intraperitoneally injected with 10 mg/ kg SB203580 or DMSO. After 2 h, mice were intravenously infused with the E
Control Shrna Constructs, supplied by OriGene, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+cd36/CD36+Human+shRNA+Plasmid+Kit/bio_rxiv__2023__01__28__526013-45-3-6
Average 92 stars, based on 1 article reviews
control shrna constructs - by Bioz Stars, 2026-11
92/100 stars
  Buy from Supplier

94
R&D Systems cd36
HUVAS adipocytes are characterized by AMPK activation and high fatty acid uptake. A, B: Capillary Western blot analysis of p-AMPK T172 , total AMPK, p-HSL S660 , p-HSL S563 (shown with 2 contrasts), total HSL, and <t>CD36</t> as well as quantification of the p-AMPK/AMPK and p-HSL/HSL ratios after normalization to total protein levels (Fig. S6A, S7A) across HUVAS, 2D, and 3D cultures from 3 technical replicates of the same individual on d30. C, D, isoprenaline-induced (C, shown as induced/basal) and basal (D) lipolysis measured by glycerol release across cultures from 8 technical replicates of the same individual. Similar results were obtained from cells from >three different cell donors. E, F: Quantification of the uptake of a BODIPY-labelled long-chain fatty acid tracer (BODIPY-FA) across HUVAS, 3D, and 2D cultures (E), and in HUVAS and 3D cultures in the absence or presence of the CD36 inhibitor SMS121 or vehicle (F). N ≥ 5 throughout; values in (F) are expressed as relative to the mean of HUVAS control to combine data from several experiments and cell donors. G–H: Quantification of CD36 mRNA expression expressed as normalized counts (G) and protein from capillary Western blot analysis (H) after normalization to total protein levels ( A) from 3 technical replicates of the same individual on d30. I–K: Effects of chronic treatment of HUVAS with CD36 inhibitor SMS121 d20-d30 shown as representative confocal images at d30 (I), adipocyte lipid droplet diameter (J), and unilocularity (K). n = 40 cells per spheroid and 2 spheroids per individual. Scale bars: 50 μm.
Cd36, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+cd36/Human+CD36%2FSR-B3+Antibody/pmc13091052-54-88-91
Average 94 stars, based on 1 article reviews
cd36 - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

91
R&D Systems recombinant human cd36
HUVAS adipocytes are characterized by AMPK activation and high fatty acid uptake. A, B: Capillary Western blot analysis of p-AMPK T172 , total AMPK, p-HSL S660 , p-HSL S563 (shown with 2 contrasts), total HSL, and <t>CD36</t> as well as quantification of the p-AMPK/AMPK and p-HSL/HSL ratios after normalization to total protein levels (Fig. S6A, S7A) across HUVAS, 2D, and 3D cultures from 3 technical replicates of the same individual on d30. C, D, isoprenaline-induced (C, shown as induced/basal) and basal (D) lipolysis measured by glycerol release across cultures from 8 technical replicates of the same individual. Similar results were obtained from cells from >three different cell donors. E, F: Quantification of the uptake of a BODIPY-labelled long-chain fatty acid tracer (BODIPY-FA) across HUVAS, 3D, and 2D cultures (E), and in HUVAS and 3D cultures in the absence or presence of the CD36 inhibitor SMS121 or vehicle (F). N ≥ 5 throughout; values in (F) are expressed as relative to the mean of HUVAS control to combine data from several experiments and cell donors. G–H: Quantification of CD36 mRNA expression expressed as normalized counts (G) and protein from capillary Western blot analysis (H) after normalization to total protein levels ( A) from 3 technical replicates of the same individual on d30. I–K: Effects of chronic treatment of HUVAS with CD36 inhibitor SMS121 d20-d30 shown as representative confocal images at d30 (I), adipocyte lipid droplet diameter (J), and unilocularity (K). n = 40 cells per spheroid and 2 spheroids per individual. Scale bars: 50 μm.
Recombinant Human Cd36, supplied by R&D Systems, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+cd36/Recombinant+Human+CD36+GST+(N-Term)+Protein/pmc04672576-111-24-27
Average 91 stars, based on 1 article reviews
recombinant human cd36 - by Bioz Stars, 2026-11
91/100 stars
  Buy from Supplier

93
fluidigm 3152007b
HUVAS adipocytes are characterized by AMPK activation and high fatty acid uptake. A, B: Capillary Western blot analysis of p-AMPK T172 , total AMPK, p-HSL S660 , p-HSL S563 (shown with 2 contrasts), total HSL, and <t>CD36</t> as well as quantification of the p-AMPK/AMPK and p-HSL/HSL ratios after normalization to total protein levels (Fig. S6A, S7A) across HUVAS, 2D, and 3D cultures from 3 technical replicates of the same individual on d30. C, D, isoprenaline-induced (C, shown as induced/basal) and basal (D) lipolysis measured by glycerol release across cultures from 8 technical replicates of the same individual. Similar results were obtained from cells from >three different cell donors. E, F: Quantification of the uptake of a BODIPY-labelled long-chain fatty acid tracer (BODIPY-FA) across HUVAS, 3D, and 2D cultures (E), and in HUVAS and 3D cultures in the absence or presence of the CD36 inhibitor SMS121 or vehicle (F). N ≥ 5 throughout; values in (F) are expressed as relative to the mean of HUVAS control to combine data from several experiments and cell donors. G–H: Quantification of CD36 mRNA expression expressed as normalized counts (G) and protein from capillary Western blot analysis (H) after normalization to total protein levels ( A) from 3 technical replicates of the same individual on d30. I–K: Effects of chronic treatment of HUVAS with CD36 inhibitor SMS121 d20-d30 shown as representative confocal images at d30 (I), adipocyte lipid droplet diameter (J), and unilocularity (K). n = 40 cells per spheroid and 2 spheroids per individual. Scale bars: 50 μm.
3152007b, supplied by fluidigm, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+cd36/Anti-Human+CD36+(5-271)-152Sm/pm31935371-235-231-229
Average 93 stars, based on 1 article reviews
3152007b - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

94
R&D Systems anti cd36
A-C. Flow analysis of CEACAM1-4L and <t>CD36-BioID2</t> expression in transfected HEK cells. ( A ) HEK cells untransfected controls. ( B ) HEK cells transfected with CD36-BioID2 only. ( C HEK cells transfected with both CD36-BioID2 and CEACAM1-4L. D-E . Immunoblots of HEK cells expressing only CD36-BioID2 (lane 1) or both CD36-BioID2 and CEACAM1-4L (lane 2), immunostained with antibodies to CD36 ( D ) or CEACAM1-4L ( E ). Transfected cells were grown for 4 days, incubated with 50 µM biotin overnight, washed twice with PBS, lysed with 1% NP40, incubated with streptavidin beads for 4 hrs, eluted with SDS running buffer, run on SDS gels and immunoblotted with <t>either</t> <t>anti-CD36</t> or anti-CEACAM1 antibodies.
Anti Cd36, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+cd36/Human+CD36%2FSR-B3+Alexa+Fluor%C2%AE+488-conjugated+Antibody/bio_rxiv__64898__2026__02__01__703119-97-13-17
Average 94 stars, based on 1 article reviews
anti cd36 - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

93
OriGene sr319610

Sr319610, supplied by OriGene, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+cd36/CD36+Human+siRNA+Oligo+Duplex/pmc06938262-51-9-6
Average 93 stars, based on 1 article reviews
sr319610 - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

93
OriGene tl314090

Tl314090, supplied by OriGene, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+cd36/CD36+Human+shRNA+Plasmid+Kit/pmc10432206-69-8-5
Average 93 stars, based on 1 article reviews
tl314090 - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

Image Search Results


Flow cytometry antibodies used.

Journal: Cancers

Article Title: Murlentamab, a Low Fucosylated Anti-Müllerian Hormone Type II Receptor (AMHRII) Antibody, Exhibits Anti-Tumor Activity through Tumor-Associated Macrophage Reprogrammation and T Cell Activation

doi: 10.3390/cancers13081845

Figure Lengend Snippet: Flow cytometry antibodies used.

Article Snippet: CD36-PEVio770 , Miltenyi , 130-110-742 , REA770 , .

Techniques: Flow Cytometry, In Vivo, In Vitro

Murlentamab opsonization of SKOV3-R2 + orients naïve macrophages and reprograms TAMs towards an M1-like profile. SKOV3-R2 + ovarian tumor cells were labeled with different 3C23K antibodies (3C23K-FcKO control, 3C23K-CHO normally fucosylated or murlentamab the low fucosylated form) and cultured in the presence of human monocyte-derived macrophages from healthy donors unstimulated (M0) or stimulated with M-CSF and IL-10 (TAMs). ( A ) The proportion of macrophages expressing M1/M2 membrane markers (CD32, CD64, CD80, TLR2, CD163, CD36 and CD206) was determined by flow cytometry after three days of co-culture with SKOV3-R2 + cells. ( B ) The release of cytokines (IL1β, IL12, TNFα, IL6, IFNγ, IL10) and chemokines (CCL2, CCL4, CCL5, CXCL9 and CXCL10) in the culture medium was determined by AlphaLISA after three days of co-culture with SKOV3-R2 + cells. Data shown (boxplots) are the results from three different experiments (performed with three different healthy donors). * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001. p values were determined using one-way ANOVA analysis followed by Tukey’s multiple comparisons test.

Journal: Cancers

Article Title: Murlentamab, a Low Fucosylated Anti-Müllerian Hormone Type II Receptor (AMHRII) Antibody, Exhibits Anti-Tumor Activity through Tumor-Associated Macrophage Reprogrammation and T Cell Activation

doi: 10.3390/cancers13081845

Figure Lengend Snippet: Murlentamab opsonization of SKOV3-R2 + orients naïve macrophages and reprograms TAMs towards an M1-like profile. SKOV3-R2 + ovarian tumor cells were labeled with different 3C23K antibodies (3C23K-FcKO control, 3C23K-CHO normally fucosylated or murlentamab the low fucosylated form) and cultured in the presence of human monocyte-derived macrophages from healthy donors unstimulated (M0) or stimulated with M-CSF and IL-10 (TAMs). ( A ) The proportion of macrophages expressing M1/M2 membrane markers (CD32, CD64, CD80, TLR2, CD163, CD36 and CD206) was determined by flow cytometry after three days of co-culture with SKOV3-R2 + cells. ( B ) The release of cytokines (IL1β, IL12, TNFα, IL6, IFNγ, IL10) and chemokines (CCL2, CCL4, CCL5, CXCL9 and CXCL10) in the culture medium was determined by AlphaLISA after three days of co-culture with SKOV3-R2 + cells. Data shown (boxplots) are the results from three different experiments (performed with three different healthy donors). * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001. p values were determined using one-way ANOVA analysis followed by Tukey’s multiple comparisons test.

Article Snippet: CD36-PEVio770 , Miltenyi , 130-110-742 , REA770 , .

Techniques: Labeling, Cell Culture, Derivative Assay, Expressing, Membrane, Flow Cytometry, Co-Culture Assay

Fig. 6 | CD36 deficiency or CD36 blockade in vivo attenuates E protein- enhanced thrombosis. a Levels of CD36 in wild-type (WT) and CD36−/−mouse platelets. Results were confirmed in three independent experiments using platelets from different mice. b and c WT and CD36−/−mice were intravenously injected with the E protein (4 μg per mouse) or PBS 4 h before the pulmonary embolism (PE) model. b Quantification of the numbers of lung embolisms per visual field on lung sections. Data are mean ± SD of 25 counts from 5 mice in each group. c Representative field on lung sections by hematoxylin-eosin (HE) staining from WT and CD36−/−mice injected with the E protein or PBS. Scale bar = 100 μm. d and e Inferior vena cava (IVC) stenosis model was performed in WT and CD36−/−mice. WT and CD36−/−mice were pretreated with the E protein (4 μg per mouse) or PBS. d Representative image of the IVC thrombi. e The quantification analysis of the thrombi weight (n = 5). f and g WT mice were intraperitoneally injected with 10 mg/ kg SB203580 or DMSO. After 2 h, mice were intravenously infused with the E

Journal: Nature communications

Article Title: CD36 mediates SARS-CoV-2-envelope-protein-induced platelet activation and thrombosis.

doi: 10.1038/s41467-023-40824-7

Figure Lengend Snippet: Fig. 6 | CD36 deficiency or CD36 blockade in vivo attenuates E protein- enhanced thrombosis. a Levels of CD36 in wild-type (WT) and CD36−/−mouse platelets. Results were confirmed in three independent experiments using platelets from different mice. b and c WT and CD36−/−mice were intravenously injected with the E protein (4 μg per mouse) or PBS 4 h before the pulmonary embolism (PE) model. b Quantification of the numbers of lung embolisms per visual field on lung sections. Data are mean ± SD of 25 counts from 5 mice in each group. c Representative field on lung sections by hematoxylin-eosin (HE) staining from WT and CD36−/−mice injected with the E protein or PBS. Scale bar = 100 μm. d and e Inferior vena cava (IVC) stenosis model was performed in WT and CD36−/−mice. WT and CD36−/−mice were pretreated with the E protein (4 μg per mouse) or PBS. d Representative image of the IVC thrombi. e The quantification analysis of the thrombi weight (n = 5). f and g WT mice were intraperitoneally injected with 10 mg/ kg SB203580 or DMSO. After 2 h, mice were intravenously infused with the E

Article Snippet: Anti-phospho-p38 (1:1000, clone D3F9, #4511, CST), anti-p38 (1:1000, clone D13E1, #8690, CST), antiphospho-NF-κB p65 (1:1000, clone 93H1, #3033, CST), anti-NF-κB p65 (1:1000, clone D14E12, #8242, CST), anti-phospho-ERK (1:1000, clone D13.14.4E, #4370, CST), anti-ERK (1:1000, clone 137F5, #4695, CST), anti-phospho-JNK (1:1000, clone 81E11, #4668, CST), anti-JNK (1:1000, clone 56G8, #9258, CST), anti-ICAM-1 (1:1000, #4915, CST), anti-VCAM-1(1:1000, clone E1E8X, #13662, CST), anti-human CD36 (1 μg/mL, #MAB1955, R&D Systems), anti-mouse CD36 (1 μg/mL, SMφ, #sc-7309, Santa Cruz), anti-His-Tag (1:2000, clone AMC0149, #AE003, ABclonal Technology), anti-Human IgG Fc (HRP)(1:3000, #ab97225, Abcam), and biotin-conjugated anti-SARS-CoV-2 envelope (1 μg/mL, #ab284658, Abcam) antibodies were used as primary antibodies.

Techniques: In Vivo, Injection, Staining

HUVAS adipocytes are characterized by AMPK activation and high fatty acid uptake. A, B: Capillary Western blot analysis of p-AMPK T172 , total AMPK, p-HSL S660 , p-HSL S563 (shown with 2 contrasts), total HSL, and CD36 as well as quantification of the p-AMPK/AMPK and p-HSL/HSL ratios after normalization to total protein levels (Fig. S6A, S7A) across HUVAS, 2D, and 3D cultures from 3 technical replicates of the same individual on d30. C, D, isoprenaline-induced (C, shown as induced/basal) and basal (D) lipolysis measured by glycerol release across cultures from 8 technical replicates of the same individual. Similar results were obtained from cells from >three different cell donors. E, F: Quantification of the uptake of a BODIPY-labelled long-chain fatty acid tracer (BODIPY-FA) across HUVAS, 3D, and 2D cultures (E), and in HUVAS and 3D cultures in the absence or presence of the CD36 inhibitor SMS121 or vehicle (F). N ≥ 5 throughout; values in (F) are expressed as relative to the mean of HUVAS control to combine data from several experiments and cell donors. G–H: Quantification of CD36 mRNA expression expressed as normalized counts (G) and protein from capillary Western blot analysis (H) after normalization to total protein levels ( A) from 3 technical replicates of the same individual on d30. I–K: Effects of chronic treatment of HUVAS with CD36 inhibitor SMS121 d20-d30 shown as representative confocal images at d30 (I), adipocyte lipid droplet diameter (J), and unilocularity (K). n = 40 cells per spheroid and 2 spheroids per individual. Scale bars: 50 μm.

Journal: Journal of Lipid Research

Article Title: Aerobic glycolysis drives differentiation of unilocular adipocytes

doi: 10.1016/j.jlr.2026.101023

Figure Lengend Snippet: HUVAS adipocytes are characterized by AMPK activation and high fatty acid uptake. A, B: Capillary Western blot analysis of p-AMPK T172 , total AMPK, p-HSL S660 , p-HSL S563 (shown with 2 contrasts), total HSL, and CD36 as well as quantification of the p-AMPK/AMPK and p-HSL/HSL ratios after normalization to total protein levels (Fig. S6A, S7A) across HUVAS, 2D, and 3D cultures from 3 technical replicates of the same individual on d30. C, D, isoprenaline-induced (C, shown as induced/basal) and basal (D) lipolysis measured by glycerol release across cultures from 8 technical replicates of the same individual. Similar results were obtained from cells from >three different cell donors. E, F: Quantification of the uptake of a BODIPY-labelled long-chain fatty acid tracer (BODIPY-FA) across HUVAS, 3D, and 2D cultures (E), and in HUVAS and 3D cultures in the absence or presence of the CD36 inhibitor SMS121 or vehicle (F). N ≥ 5 throughout; values in (F) are expressed as relative to the mean of HUVAS control to combine data from several experiments and cell donors. G–H: Quantification of CD36 mRNA expression expressed as normalized counts (G) and protein from capillary Western blot analysis (H) after normalization to total protein levels ( A) from 3 technical replicates of the same individual on d30. I–K: Effects of chronic treatment of HUVAS with CD36 inhibitor SMS121 d20-d30 shown as representative confocal images at d30 (I), adipocyte lipid droplet diameter (J), and unilocularity (K). n = 40 cells per spheroid and 2 spheroids per individual. Scale bars: 50 μm.

Article Snippet: Immunoblotting was performed using the following primary antibodies against: PLIN1 (1:10, PA5-81240, Fisher Scientific), CIDEC (1:10, PA1-46128, Invitrogen), UCP1 (1:50, MAB6158, R&D Systems), PPARγ (1:50, 2435S, Cell Signaling), FAS (1:50, 3180, BioTechne), ATGL (1:50, 2138, Cell Signaling), Total OXPHOS cocktail (1:50, Ab110411 , Abcam), TOMM20 (1:50, NBP1-81556, BioTechne), PTP1B (1:50, Ab244207 , Abcam), HIF1α (1:100, NBP2-75977, Novus), P-AMPK (Thr172, 1:10, 2535, Cell Signaling), total AMPK (1:50, 2532, Cell Signaling), P-HSL (Ser660, 1:10, 45,804, Cell Signaling), P-HSL (Ser563, 1:10, 4139, Cell Signaling), total HSL (1:50, 4107, Cell Signaling), and CD36 (1:50, AF1955, R&D Systems).

Techniques: Activation Assay, Western Blot, Control, Expressing

A-C. Flow analysis of CEACAM1-4L and CD36-BioID2 expression in transfected HEK cells. ( A ) HEK cells untransfected controls. ( B ) HEK cells transfected with CD36-BioID2 only. ( C HEK cells transfected with both CD36-BioID2 and CEACAM1-4L. D-E . Immunoblots of HEK cells expressing only CD36-BioID2 (lane 1) or both CD36-BioID2 and CEACAM1-4L (lane 2), immunostained with antibodies to CD36 ( D ) or CEACAM1-4L ( E ). Transfected cells were grown for 4 days, incubated with 50 µM biotin overnight, washed twice with PBS, lysed with 1% NP40, incubated with streptavidin beads for 4 hrs, eluted with SDS running buffer, run on SDS gels and immunoblotted with either anti-CD36 or anti-CEACAM1 antibodies.

Journal: bioRxiv

Article Title: Direct interactions of CEACAM1 and CD36 with LPS and each other

doi: 10.64898/2026.02.01.703119

Figure Lengend Snippet: A-C. Flow analysis of CEACAM1-4L and CD36-BioID2 expression in transfected HEK cells. ( A ) HEK cells untransfected controls. ( B ) HEK cells transfected with CD36-BioID2 only. ( C HEK cells transfected with both CD36-BioID2 and CEACAM1-4L. D-E . Immunoblots of HEK cells expressing only CD36-BioID2 (lane 1) or both CD36-BioID2 and CEACAM1-4L (lane 2), immunostained with antibodies to CD36 ( D ) or CEACAM1-4L ( E ). Transfected cells were grown for 4 days, incubated with 50 µM biotin overnight, washed twice with PBS, lysed with 1% NP40, incubated with streptavidin beads for 4 hrs, eluted with SDS running buffer, run on SDS gels and immunoblotted with either anti-CD36 or anti-CEACAM1 antibodies.

Article Snippet: On day 4 following transfection, the cells were collected and stained with either anti-CD36 (FAB19551G) or anti-CEACAM-1 (R&D systems, FAB2244P) antibody to assess the level of expression using flow cytometry.

Techniques: Expressing, Transfection, Western Blot, Incubation

Journal: Cell reports

Article Title: CD36-Mediated Metabolic Rewiring of Breast Cancer Cells Promotes Resistance to HER2-Targeted Therapies

doi: 10.1016/j.celrep.2019.11.008

Figure Lengend Snippet:

Article Snippet: CD36 Human siRNA Oligo Duplex , Origene , Cat# SR319610.

Techniques: Blocking Assay, Control, Recombinant, Isolation, cDNA Synthesis, SYBR Green Assay, Transfection, Proliferation Assay, Microarray, Negative Control, Software

Journal: iScience

Article Title: Targeting CD36 determines nicotine derivative NNK-induced lung adenocarcinoma carcinogenesis

doi: 10.1016/j.isci.2023.107477

Figure Lengend Snippet:

Article Snippet: CD36 shRNA: 5'-GGACCATTGGTGATGAGAAGG CAAACATG-3' , Origene , Cat# TL314090.

Techniques: Recombinant, Virus, Subcloning, Plasmid Preparation, shRNA, Software